Main Article Content
Background: Hypertension and dyslipidemia are strongly associated with each other, and they are the most common risk factors for the development of the cardiovascular disease.
Aim: Compare the serum lipid profile values among hypertensive patients and non-hypertensive individuals.
Method: 30 patients with Hypertension and 30 age-matched non-hypertensive controls were included in the study. From the serum, total cholesterol levels were estimated by enzymatic (CHOD-PAP) colorimetric method, triglyceride by enzymatic (GPO-PAP) method, HDL-cholesterol and LDL-cholesterol were estimated using precipitant and Friedewald formula, by using commercially available reagent kits. Lipid profiles were compared with controls.
Results: The mean values of total cholesterol were significantly more in Hypertensives-202.93 ± 28.44 and normotensives-178.76 ± 37.21, P<0.006. The mean values of triglycerides were significantly more in Hypertensives-139.8 ± 18.72 and normotensives-125.8± 12.34, P<0.001. The mean values of LDL-Cholesterol were significantly more in Hypertensives-141.63 ± 11.59 and normotensives-127.83 ± 14.65, P<0.0001.
Conclusions: As Dyslipidemia is associated with Hypertension, serum lipid profile may be useful in the identification of patients at risk of Hypertension. Hypertensive patients need the measurement of blood pressure and lipid profile at regular intervals to prevent Cardiovascular diseases.
Keywords: Cholesterol; Cardiovascular Diseases; Hypertension; Triglycerides; Dyslipidemia.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.
Joshi P, Islam S, Pais P, Reddy S, Dorairaj P, Kazmi K, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297(3):286–94
Kumar A, Nagtilak S, Sivakanesan R, Gunasekera S. Cardio-vascular risk factors in elderly Normolipidimic acute myocardial infarction patients – A case-controlled study from India. Southeast Asian J Trop Med Public Health. 2009;40(3):581–92
Wannarinthee SC, Shaper AG, Durington PN, Perry M. Metabolic Syndrome. J. Human Hypertension, 1998;12(2): 1059-64.
Lipid Research Clinic Program. The lipid research clinic coronary primary prevention trial results II. J.Am. Med. Assoc. 1984;251:364-74.
Fogelman A, I. Schechter J. Seager. Alteration of low density lipoproteins leads to cholesterylester accumulation in human monocyte macrophages. Proc. Natl. Acad. Sci., USA, 1980;77:2214-8
Palinski W, Rosenfeld M, Yla-Herttuala S. Low density lipoprotein undergoes oxidative modification in vivo. Proc.Natl. Acad. Sci., USA. 1989;86:1372-6.
Allain CC, Poon IS, Chan CHG, Richmond W, Fu PC. Enzymatic determination of serum total cholesterol.Clin. Chem. 1974; 20: 470-1
Jacobs NJ, VanDenmark PJ. Enzymatic determination of serum triglyceride.ch. Biochem. Biophys. 1960;88:250-5.
Gordon T and Gordon M, Enzymatic method to determine the serum HDL-cholesterol. Am. J. Med. 1977; 62: 707-8
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-cholesterol. Clin. Chem. 1972;18 (6): 499-515
Third Report of the National Cholesterol Education Program (NCEP), “Expert panel on detection, evaluation, and treat- ment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, 2002; 106: 3143–421.
Sabri S, Bener A, Eapen V, Abu Zeid MS, Al- Mazrouei AM, Singh J. Some risk factors for hypertension in the United Arab Emirates. East Mediterr Health J. 2004; 10(4-5):610-9
Yin R, Chen Y, Pan S, He F, Liu T, Yang D, et al. Comparison of lipid levels, hyperlipidemia prevalence and its risk factors between Guangxi Hei Yi Zhuang and Han populations. Arch Med Res. 2006;37(6):787-93.
Shahadat H, Maliha R, Iqbal A, Suhrab A. Study of serum lipid profile in essential hypertensive patients. Mym Med J. 1999;8(1):22–5.
Adedeji OO, Onitiri AC. Lipids in Nigerian hypertensives. Afr J Med Sci. 1990;19:281–4.
Saha MS, Saha NK, Shaha RK. Serum lipid profile of hypertensive patients in the northern region of Bangladesh. J Biosci. 2006;14:93
Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-76.
Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997;95:5-7.
Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
Schaeffner ES, Kurth T, Curhan GC, Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084- 91.